Literature DB >> 28332166

Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients.

Yuki Osada1, Hideki Arakaki1, Satoshi Takanashi1, Chisako Ito1, Yoshinobu Aisa1, Tomonori Nakazato2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28332166     DOI： 10.1007/s12032-017-0922-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  7 in total

1.  Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study.

Authors:  Kunihiro Nishimura; Tomonori Okamura; Makoto Watanabe; Michikazu Nakai; Misa Takegami; Aya Higashiyama; Yoshihiro Kokubo; Akira Okayama; Yoshihiro Miyamoto
Journal:  J Atheroscler Thromb       Date:  2014-03-25       Impact factor: 4.928

2.  Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population-Based Cohort Study.

Authors:  Torsten Dahlén; Gustaf Edgren; Mats Lambe; Martin Höglund; Magnus Björkholm; Fredrik Sandin; Anders Själander; Johan Richter; Ulla Olsson-Strömberg; Lotta Ohm; Magnus Bäck; Leif Stenke
Journal:  Ann Intern Med       Date:  2016-06-14       Impact factor: 25.391

3.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Authors:  Karl J Aichberger; Susanne Herndlhofer; Gerit-Holger Schernthaner; Martin Schillinger; Gerlinde Mitterbauer-Hohendanner; Christian Sillaber; Peter Valent
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047

4.  Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.

Authors:  D Rea; T Mirault; E Raffoux; N Boissel; A L Andreoli; P Rousselot; H Dombret; E Messas
Journal:  Leukemia       Date:  2014-12-08       Impact factor: 11.528

5.  Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.

Authors:  Jonathan Douxfils; Hélène Haguet; François Mullier; Christian Chatelain; Carlos Graux; Jean-Michel Dogné
Journal:  JAMA Oncol       Date:  2016-05-01       Impact factor: 31.777

6.  Cardiovascular risk assessments in chronic myeloid leukemia allow identification of patients at high risk of cardiovascular events during treatment with nilotinib.

Authors:  Massimo Breccia; Gioia Colafigli; Matteo Molica; Giuliana Alimena
Journal:  Am J Hematol       Date:  2015-05       Impact factor: 10.047

7.  Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment.

Authors:  Massimo Breccia; Matteo Molica; Irene Zacheo; Alessandra Serrao; Giuliana Alimena
Journal:  Ann Hematol       Date:  2014-10-12       Impact factor: 3.673
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.